An engineered heart patch from embryonic stem cells

由胚胎干细胞改造而成的心脏补片

基本信息

  • 批准号:
    BB/D011027/1
  • 负责人:
  • 金额:
    $ 61.64万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2006
  • 资助国家:
    英国
  • 起止时间:
    2006 至 无数据
  • 项目状态:
    已结题

项目摘要

The heart does not have the capacity to self-repair, so loss of muscle tissue following a heart attack leaves it permanently weakened. Many researchers are aiming to use cells to repair this damage, but the exact type of cell and the way to introduce them into the heart is a matter of great debate. In the present study we will use cardiac muscle cells (myocytes) grown from embryonic stem cells. These have the advantage that there is a steady supply, since the ES cells will divide continuously in culture before being directed into different cell types. We are able to grow human and mouse ES cells and convert them to beating myocytes: in both cases we use existing cell lines. Most studies have introduced new cells into the heart by injecting them in a fluid suspension. However, many cells are lost within the first week after injection. If the heart attack was not recent, scar tissue develops, and cells injected into this do not receive a blood supply or connect electrically to the rest of the heart. We therefore want to grow the cells on a patch of material and graft it to the heart. This will overcome the problems associated with cell injection and will have the added advantage that the patch can prevent the scar from stretching. Containing the heart within a scaffold to prevent it from expanding is already being tried as a therapy by itself. We intend to develop a suitable material which can be used as a support for the growth of ES cells and then sewn into place on the heart. It will need to have properties such as biocompatibility, strength and the ability to withstand repeated stretch. It will be designed to degrade slowly when in the body, so that the patch material will disappear as the grafted cells integrate into the heart. We will first test the ability of ES cells to grow and become myocytes when cultured on the patch. A detailed profile of the myocytes can be built up in terms of shape and size, contraction and relaxation characteristics, responses to hormones and drugs, and electrical coupling. These can be compared with our normal cultures, and with adult human and mouse cells which we also study. Stretching and electrical stimulation will be applied to the patch with cells, to try to develop the heart muscle and stimulate the growth of blood vessels. The effect of the patch itself will be tested on an animal model, where a myocardial infarction (heart attack) is produced in rat. This model mimics the human disease in many aspects. We will determine whether grafting of the patch is able to slow the development of heart failure and prevent the heart from expanding. When the patch is optimised for both cell growth and grafting, the combined effect of the patch plus cells will be studied. The key things we will be looking for are the integration of the grafted cells into the heart, the development of electrical connections, the growth of blood vessels and an improvement in the function of the heart. The project will require the combined expertise of the biologists of the National Heart and Lung Institute and the engineers of the Department of Materials for biomaterial engineering, ES cell culture, myocyte generation, myocyte characterisation and animal surgery.
心脏没有自我修复的能力,因此心脏病发作后肌肉组织的损失会使其永久性地减弱。许多研究人员的目标是使用细胞来修复这种损伤,但细胞的确切类型以及将它们引入心脏的方法是一个有争议的问题。在本研究中,我们将使用从胚胎干细胞中培养的心肌细胞(肌细胞)。这些具有稳定供应的优点,因为ES细胞在被定向成不同细胞类型之前将在培养中连续分裂。我们能够培养人类和小鼠的ES细胞,并将它们转化为跳动的肌细胞:在这两种情况下,我们都使用现有的细胞系。大多数研究都是通过将新细胞注射到液体悬浮液中来将它们引入心脏。然而,许多细胞在注射后的第一周内丢失。如果心脏病不是最近发作的,疤痕组织就会发展,注入其中的细胞不会接受血液供应或与心脏的其他部分电连接。因此,我们希望在一块材料上培养细胞,并将其移植到心脏上。这将克服与细胞注射相关的问题,并将具有额外的优势,即贴片可以防止疤痕拉伸。将心脏放在支架内以防止其扩张已经被尝试作为一种治疗方法。我们打算开发一种合适的材料,可以用作ES细胞生长的支持物,然后将其缝在心脏上。它需要具有生物相容性、强度和承受反复拉伸的能力等特性。它将被设计成在体内缓慢降解,这样当移植的细胞整合到心脏中时,补丁材料就会消失。我们将首先测试ES细胞在贴片上培养时生长并成为肌细胞的能力。可以根据形状和大小、收缩和舒张特性、对激素和药物的反应以及电耦合来建立肌细胞的详细轮廓。这些可以与我们的正常培养物以及我们也研究的成人和小鼠细胞进行比较。拉伸和电刺激将应用于细胞贴片,试图发展心肌和刺激血管的生长。贴剂本身的效果将在动物模型上进行测试,其中在大鼠中产生心肌梗死(心脏病发作)。该模型在许多方面模拟了人类疾病。我们将确定移植补片是否能够减缓心力衰竭的发展并防止心脏扩张。当贴片针对细胞生长和移植两者进行优化时,将研究贴片加细胞的组合效果。我们将寻找的关键是移植细胞与心脏的整合,电连接的发展,血管的生长和心脏功能的改善。该项目将需要国家心肺研究所的生物学家和材料部的工程师在生物材料工程、ES细胞培养、肌细胞生成、肌细胞表征和动物手术方面的综合专业知识。

项目成果

期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy?
  • DOI:
    10.1016/j.yjmcc.2010.10.029
  • 发表时间:
    2011-02
  • 期刊:
  • 影响因子:
    5
  • 作者:
    Földes G;Mioulane M;Wright JS;Liu AQ;Novak P;Merkely B;Gorelik J;Schneider MD;Ali NN;Harding SE
  • 通讯作者:
    Harding SE
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sian Harding其他文献

An evaluation of Scottish green health prescriptions using the APEASE criteria
  • DOI:
    10.1186/s12875-025-02746-9
  • 发表时间:
    2025-02-22
  • 期刊:
  • 影响因子:
    2.600
  • 作者:
    Neil Howlett;Imogen Freethy;Sian Harding;Adam P. Wagner;Lisa Miners;Honey Anne-Greco;Laura Lamming;Nigel Lloyd;Katherine E. Brown
  • 通讯作者:
    Katherine E. Brown
Heterogeneous SERCA2a transfection reduces ventricular arrhythmias in the rat model of heart failure
  • DOI:
    10.1016/j.yjmcc.2008.02.010
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Alexander Lyon;Amir Sepehripour;Sukhpreet Dubb;Ken Macleod;Philip Poole-Wilson;Nicholas Peters;Sian Harding
  • 通讯作者:
    Sian Harding
Cellular dysfunction and altered contractile protein post-translational modification in hypertrophic cardiomyopathy septal tissue
  • DOI:
    10.1016/j.yjmcc.2008.02.084
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Clare Gallon;Edwin Garcia;Gaelle Kikonda Kanda;Andrew Messer;Sian Harding;Steven Marston
  • 通讯作者:
    Steven Marston
Investigation of a mouse model of familial DCM with ACTC E361G mutation
  • DOI:
    10.1016/j.yjmcc.2008.02.261
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Weihua Song;Emma Dyer;Dominic Wells;Sian Harding;Daniel Stuckey;Carolyn Carr;Kieran Clarke;Steven Marston
  • 通讯作者:
    Steven Marston
Procedures and iatrogenic disorders
手术和医源性疾病
  • DOI:
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sian Harding
  • 通讯作者:
    Sian Harding

Sian Harding的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sian Harding', 18)}}的其他基金

iPSC-derived cardiomyocytes to model estrogen receptor modulation of stress cardiomyopathy and arrhythmic syndromes
iPSC 衍生的心肌细胞模拟应激性心肌病和心律失常综合征的雌激素受体调节
  • 批准号:
    MR/M010422/1
  • 财政年份:
    2015
  • 资助金额:
    $ 61.64万
  • 项目类别:
    Research Grant
BHF Imperial Cardiovascular Regenerative Medicine Centre
BHF帝国心血管再生医学中心
  • 批准号:
    MR/L012618/1
  • 财政年份:
    2013
  • 资助金额:
    $ 61.64万
  • 项目类别:
    Research Grant
Stem cell-derived cardiomyocytes for detection of cardiotoxicity in cancer therapeutics
干细胞衍生的心肌细胞用于检测癌症治疗中的心脏毒性
  • 批准号:
    G1000035/1
  • 财政年份:
    2010
  • 资助金额:
    $ 61.64万
  • 项目类别:
    Research Grant

相似国自然基金

SIRT2在灵长类心肌衰老进程中的作用及其机制研究
  • 批准号:
    32000510
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
心衰中miR214调控Junctophilin-2的机制研究
  • 批准号:
    81170225
  • 批准年份:
    2011
  • 资助金额:
    14.0 万元
  • 项目类别:
    面上项目
抑制 miR-21 (微小RNA-21) 过表达对心肌重构和心力衰竭改善和治疗作用的研究
  • 批准号:
    81070128
  • 批准年份:
    2010
  • 资助金额:
    32.0 万元
  • 项目类别:
    面上项目
心脏超声造影的安全性研究
  • 批准号:
    30870721
  • 批准年份:
    2008
  • 资助金额:
    31.0 万元
  • 项目类别:
    面上项目
e-Heart仿真平台及关键技术研究
  • 批准号:
    60571025
  • 批准年份:
    2005
  • 资助金额:
    24.0 万元
  • 项目类别:
    面上项目
婴儿复杂型先心病无创心内三维虚拟现实诊断方法研究
  • 批准号:
    30371497
  • 批准年份:
    2003
  • 资助金额:
    20.0 万元
  • 项目类别:
    面上项目

相似海外基金

A New Approach to Vascular Reconstruction using Graphical 3D Printing and Flow Modelling to create personalised precision engineered surgery
使用图形 3D 打印和流动建模进行血管重建的新方法,以创建个性化的精密工程手术
  • 批准号:
    463878
  • 财政年份:
    2022
  • 资助金额:
    $ 61.64万
  • 项目类别:
    Operating Grants
Engineered BacNav and BacCav for Improved Excitability and Contraction
专为改善兴奋性和收缩性而设计的 BacNav 和 BacCav
  • 批准号:
    10392121
  • 财政年份:
    2022
  • 资助金额:
    $ 61.64万
  • 项目类别:
Engineered BacNav and BacCav for Improved Excitability and Contraction
专为改善兴奋性和收缩性而设计的 BacNav 和 BacCav
  • 批准号:
    10611385
  • 财政年份:
    2022
  • 资助金额:
    $ 61.64万
  • 项目类别:
Engineered Anisotropic and Vascularized Human Cardiac Patch
工程化各向异性和血管化人体心脏贴片
  • 批准号:
    10448375
  • 财政年份:
    2021
  • 资助金额:
    $ 61.64万
  • 项目类别:
Engineered Anisotropic and Vascularized Human Cardiac Patch
工程化各向异性和血管化人体心脏贴片
  • 批准号:
    10652538
  • 财政年份:
    2021
  • 资助金额:
    $ 61.64万
  • 项目类别:
Engineered Anisotropic and Vascularized Human Cardiac Patch
工程化各向异性和血管化人体心脏贴片
  • 批准号:
    10378333
  • 财政年份:
    2021
  • 资助金额:
    $ 61.64万
  • 项目类别:
Engineered Anisotropic and Vascularized Human Cardiac Patch
工程化各向异性和血管化人体心脏贴片
  • 批准号:
    9886725
  • 财政年份:
    2020
  • 资助金额:
    $ 61.64万
  • 项目类别:
Myocardial Repair with a Novel Engineered Cardiac Muscle Patch
使用新型工程心肌补片修复心肌
  • 批准号:
    10229464
  • 财政年份:
    2019
  • 资助金额:
    $ 61.64万
  • 项目类别:
Myocardial Repair with a Novel Engineered Cardiac Muscle Patch
使用新型工程心肌补片修复心肌
  • 批准号:
    10471216
  • 财政年份:
    2019
  • 资助金额:
    $ 61.64万
  • 项目类别:
Myocardial Repair with a Novel Engineered Cardiac Muscle Patch
使用新型工程心肌补片修复心肌
  • 批准号:
    10002275
  • 财政年份:
    2019
  • 资助金额:
    $ 61.64万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了